Medtronic Cardio/Neuro Buys Stimulate Wall Street In 1998 - Stock Up 42%
This article was originally published in The Gray Sheet
Medtronic's tried and true ability to post solid operating results while simultaneously revamping its product profile to meet shifting market demands provided Wall Street with a dual reason to reward the firm's share price in 1998. The company's stock gained 41.5%, or 21-3/4 points, to close the year at 74-9/32.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.